OncoMatch/Clinical Trials/NCT05797467
Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
Is NCT05797467 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including FOLFOX chemotherapy regimens and Bevacizumab for colorectal cancer.
Treatment: FOLFOX chemotherapy regimens · Bevacizumab — The goal of this clinical trial\] is to compare in resectable stage T3-4N2 colorectal cancer. The main question it aims to answer is: whether the use of targeted therapy in combination with adjuvant chemotherapy is associated with improved disease-free survival (DFS) compared to adjuvant chemotherapy alone.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage PT3, PT4
pT3-4N2 stage colorectal adenocarcinoma after surgery
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
No coagulation dysfunction
Kidney function
No severe kidney dysfunction
Liver function
No severe liver dysfunction
Cardiac function
No severe cardio-pulmonary dysfunction
Patients with severe liver, kidney, cardio-pulmonary, coagulation dysfunction, or underlying diseases that cannot tolerate chemotherapy [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify